Literature DB >> 30840163

Obtaining Optimal Long-Term Outcomes from Liver Transplantation for Hepatocellular Cancer.

Trevor W Reichman1, Chandra S Bhati2, Narendra R Battula3.   

Abstract

Liver transplantation is the definitive treatment for patients with end-stage liver disease. Liver transplantation is also the optimal treatment for patients with hepatocellular carcinoma (HCC), especially in the setting of chronic liver disease. Unfortunately, due to the worldwide shortage of organs, this treatment is not available for all patients with HCC. Strict selection criteria have been developed in order to obtain optimal results. A surgical perspective of the preoperative selection, perioperative management, and postoperative care of patients is reviewed in depth and provides an overview for obtaining optimal long-term results from liver transplantation for HCC. With rigorous selection and patient management, excellent long-term outcomes can be obtained with liver transplantation for patients with HCC.

Entities:  

Keywords:  Hepatocellular cancer; Liver transplantation; Outcomes

Mesh:

Year:  2019        PMID: 30840163     DOI: 10.1007/s10620-019-05550-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  82 in total

1.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

2.  Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?

Authors:  Elena Fernandez-Sevilla; Marc-Antoine Allard; Jasmijn Selten; Nicolas Golse; Eric Vibert; Antonio Sa Cunha; Daniel Cherqui; Denis Castaing; René Adam
Journal:  Liver Transpl       Date:  2017-04       Impact factor: 5.799

3.  Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.

Authors:  Laura Kulik; Michael Vouche; Sean Koppe; Robert J Lewandowski; Mary F Mulcahy; Daniel Ganger; Ali Habib; Jennifer Karp; Patrice Al-Saden; Mario Lacouture; Jonathan Cotliar; Michael Abecassis; Talia Baker; Riad Salem
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

4.  The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.

Authors:  Gonzalo Sapisochin; Nicolas Goldaracena; Jerome M Laurence; Martin Dib; Andrew Barbas; Anand Ghanekar; Sean P Cleary; Les Lilly; Mark S Cattral; Max Marquez; Markus Selzner; Eberhard Renner; Nazia Selzner; Ian D McGilvray; Paul D Greig; David R Grant
Journal:  Hepatology       Date:  2016-06-30       Impact factor: 17.425

5.  Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.

Authors:  Min Woo Lee; Steven S Raman; Nazanin H Asvadi; Surachate Siripongsakun; Robert M Hicks; Jeffrey Chen; Akeanong Worakitsitisatorn; Justin McWilliams; Myron J Tong; Richard S Finn; Vatche G Agopian; Ronald W Busuttil; David S K Lu
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

Review 6.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

7.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.

Authors:  Vincenzo Mazzaferro; Josep M Llovet; Rosalba Miceli; Sherrie Bhoori; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sasan Roayaie; Myron E Schwartz; Gian Luca Grazi; René Adam; Peter Neuhaus; Mauro Salizzoni; Jordi Bruix; Alejandro Forner; Luciano De Carlis; Umberto Cillo; Andrew K Burroughs; Roberto Troisi; Massimo Rossi; Giorgio E Gerunda; Jan Lerut; Jacques Belghiti; Ilka Boin; Jean Gugenheim; Fedja Rochling; Bart Van Hoek; Pietro Majno
Journal:  Lancet Oncol       Date:  2008-12-04       Impact factor: 41.316

8.  Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.

Authors:  Norman M Kneteman; José Oberholzer; Mohammed Al Saghier; Glenda A Meeberg; Maurice Blitz; Mang M Ma; Winnie W S Wong; Klaus Gutfreund; Andrew L Mason; Larry D Jewell; A M James Shapiro; Vincent G Bain; David L Bigam
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

9.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

Authors:  Edward K Geissler; Andreas A Schnitzbauer; Carl Zülke; Philipp E Lamby; Andrea Proneth; Christophe Duvoux; Patrizia Burra; Karl-Walter Jauch; Markus Rentsch; Tom M Ganten; Jan Schmidt; Utz Settmacher; Michael Heise; Giorgio Rossi; Umberto Cillo; Norman Kneteman; René Adam; Bart van Hoek; Philippe Bachellier; Philippe Wolf; Lionel Rostaing; Wolf O Bechstein; Magnus Rizell; James Powell; Ernest Hidalgo; Jean Gugenheim; Heiner Wolters; Jens Brockmann; André Roy; Ingrid Mutzbauer; Angela Schlitt; Susanne Beckebaum; Christian Graeb; Silvio Nadalin; Umberto Valente; Victor Sánchez Turrión; Neville Jamieson; Tim Scholz; Michele Colledan; Fred Fändrich; Thomas Becker; Gunnar Söderdahl; Olivier Chazouillères; Heikki Mäkisalo; Georges-Philippe Pageaux; Rudolf Steininger; Thomas Soliman; Koert P de Jong; Jacques Pirenne; Raimund Margreiter; Johann Pratschke; Antonio D Pinna; Johann Hauss; Stefan Schreiber; Simone Strasser; Jürgen Klempnauer; Roberto I Troisi; Sherrie Bhoori; Jan Lerut; Itxarone Bilbao; Christian G Klein; Alfred Königsrainer; Darius F Mirza; Gerd Otto; Vincenzo Mazzaferro; Peter Neuhaus; Hans J Schlitt
Journal:  Transplantation       Date:  2016-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.